Vaccine combo shows early promise against AIDS

A new AIDS vaccine that combines two experimental therapies has shown promise in monkeys. The animals were given a vaccine developed by Johnson & Johnson ($JNJ) subsidiary Crucell combined with a booster created by the U.S military and the National Institute of Allergy and Infectious Diseases, and exposed to a highly immune-resistant strain of simian immunodeficiency virus (SIV), which is similar to AIDS. Those monkeys that received the combination vaccine/booster were up to 83% less likely to contract the virus, although animals that were repeatedly exposed to the disease eventually contracted SIV. The findings were published in the online edition of the journal Nature. Report | Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.